Navigation Links
Hemostemix Announces Formation of Scientific Advisory Board
Date:6/10/2013

Toronto, Ontario (PRWEB) June 10, 2013

The Hemostemix Group of Companies announced today the formation of its Scientific Advisory Board (the “Board”) and the addition of its first three members.

The Hemostemix Group is comprised of Hemostemix Ltd. (Hemostemix), a company incorporated in Israel with an operating research, development and manufacturing facility in Ness Ziona, Kwalata Trading Ltd. (“Kwalata”), registered in Cyprus, and the parent company Theravitae, Inc. (“TVI”) based in Toronto, Ontario, Canada (collectively the “Hemostemix Group” or “Group”).

The first three members of the Board to be announced are:

Dr. Heinz Redl

Heinz Redl, Ph.D. is the Chair-elect of the European Chapter of the Tissue Engineering and Regenerative Medicine International Society, head of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology and Associate Professor at the Vienna University of Technology. He is coordinator of the Austrian Cluster for Tissue Regeneration (together with the Medical University Vienna) with 5 branches – bone, cartilage, peripheral nerve, soft tissue (wound healing) and imaging - and also the CEO of the non-profit Trauma Care Consult.

Dr. Norman Wong

Norman C.W. Wong, M.D., F.R.C.P.(C) is a Fellow of The Royal College of Physicians of Canada and is currently a Professor in the Departments of Medicine, Biochemistry and Molecular Biology in the Faculty of Medicine at the University of Calgary. His previous roles include Associate VP Research and International, assistant Dean of research for the faculty of Medicine and as well as Director of the Libin Gene Therapy Unit. He has acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.

Dr. Mark Zucker

Mark Jay Zucker, M.D., J.D., F.A.C.C., F.A.C.P. is Director of the Harvey and Georgina Weinstein National Heart Transplant Center at Newark Beth Israel Medical Center and Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, N.J. Dr. Zucker graduated from Northwestern University with his medical degree and from Loyola University with a law degree. Prior to his current appointments, Dr. Zucker has served in faculty positions at Mount Sinai School of Medicine in New York and Loyola University Medical School in Illinois. He currently is Advisory Board Vice-Chair and on the Board of Directors for the New Jersey Organ & Tissue Sharing Network. He has been involved with heart and lung transplantation and mechanical circulatory support for over 25 years and has been a principal or co-investigator on more than 40 trials including trials of cell-based therapies such as the BioHeart myoblast trial and the ongoing Baxter RENEW trial.

“We are committed to having a world-class Scientific Advisory Board we can draw expertise from as we move forward with our strategy and particularly with the phase 2 trial of our cell therapy product for patients with critical limb ischemia recently cleared to proceed by Health Canada,” stated Hemostemix Group President Dr. Valentin Fulga. “Each of the three members announced today has followed our company and its technology for some time and we are very pleased they have agreed to join our SAB,” Fulga concluded.

Further announcements about additions to the Hemostemix Group’s Scientific Advisory Board are expected to be made in the near future.

About Hemostemix Ltd

Hemostemix Ltd is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. Hemostemix and Kwalata Trading Ltd (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company, Theravitae Inc (“TVI”) (collectively, the “Hemostemix Group”).    On 14 May 2013, TVI announced a letter of intent signed with Technical Ventures RX Corp (TSX-V:TIK.P) (“Technical”) regarding a proposed Qualifying Transaction in which Technical would acquire TVI and its subsidiaries in a share transaction. For more information see http://www.hemostemix.com.

Read the full story at http://www.prweb.com/releases/2013Hemostemix/SAB/prweb10807580.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Hemostemix Group of Companies Provides Corporate Strategy Update
2. Hemostemix Announces US Patent Allowance
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... UTAH. (PRWEB) , ... May 25, 2016 , ... WEDI, ... healthcare information exchange, today announced that Charles W. Stellar has been named by the ... interim CEO since January 2016. As an executive leader with more than 35 years ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... England , May 23, 2016 ... May 25 th at 10:15 a.m. ET before the ... the role genetically engineered mosquitos can play in controlling the ... carrier of the Zika virus.      (Logo: ... engineered male mosquito with a self-limiting gene. Trials in ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary ... most experienced veterinary clients have treated over 100 of their own patients with the ... provide the highest level of care for their patients. , The veterinarians are ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ... 21 st .  The commercials will air on Bloomberg TV, ... the Street show. --> NXTD ) ("NXT-ID" or ... market, announces the airing of a new series of commercials ...
Breaking Biology News(10 mins):